Chloroquine and Ixabepilone

The combination of chloroquine and ixabepilone is a therapeutic regimen that has been studied in clinical trials for the treatment of advanced or metastatic breast cancer. This combination therapy was designed to target both conventional cancer cells and cancer stem cells (CSCs), which are believed to be responsible for tumor initiation and self-renewal[1][3].\n\nIn a Phase II clinical trial, chloroquine 250 mg was administered daily orally in combination with either docetaxel, paclitaxel, nab-paclitaxel, or ixabepilone every 3 weeks for up to 6 cycles[1][3]. The study enrolled female patients aged 18 years or older who had previously received anthracycline-based chemotherapy[1][3].\n\nThe results of this trial showed promising efficacy, with an objective response rate (ORR) of 45.16%, which was higher than the expected ORR of 30%[1][3]. Patients experienced a median progression-free survival (PFS) of 12.4 months and a median overall survival (OS) of 25.4 months[1][3]. The combination was generally well-tolerated, with only 13.15% of patients experiencing grade 3 or higher adverse events[1][3].\n\n## Components of the Combination\n\n### Chloroquine\nChloroquine is traditionally known as an antimalarial drug but has been repurposed for cancer treatment. Through bioinformatics analysis, it was identified as a potential agent to target cancer stem cells[1][3]. The standard dose used in the combination therapy was 250 mg daily administered orally[1][3].\n\n### Ixabepilone\nIxabepilone is a microtubule stabilizer and inhibitor that belongs to the epothilone class of antineoplastic agents[5][6]. It is a semisynthetic analogue of epothilone B with a lactone-lactam modification that minimizes susceptibility to esterase degradation[6]. Ixabepilone is FDA-approved as a monotherapy and in combination with capecitabine for the treatment of metastatic breast cancer that has shown inadequate response to taxanes and anthracyclines[5][6].\n\n## Mechanism of Action\n\nThe combination therapy works through complementary mechanisms:\n\n1. Ixabepilone acts as a microtubule inhibitor, disrupting the normal microtubule dynamics required for cell division, thereby preventing cancer cell proliferation[5][6].\n\n2. Chloroquine appears to target cancer stem cells, which are typically resistant to conventional chemotherapy and are believed to be responsible for tumor recurrence and metastasis[1][3].\n\nThis dual approach may explain the enhanced efficacy observed in clinical trials, as it addresses both the bulk tumor cells and the cancer stem cell population that might otherwise lead to disease progression or recurrence.